Real-world Effectiveness and Causal Mediation Study of BNT162b2 on Long COVID Risks in Children and Adolescents

Qiong Wu, Bingyu Zhang, Jiayi Tong, L. Charles Bailey, H. Timothy Bunnell, Jiajie Chen, Elizabeth A. Chrischilles, Dimitri Christakis, Stephen M. Downs, Kathryn Hirabayashi, Ravi Jhaveri, Aaron Mishkin, Abu Saleh Mohammad Mosa, Nathan M. Pajor, Suchitra Rao, Hanieh Razzaghi, Hayden T. Schwenk, Marion R. Sills, Huiyuan Wang, Linbo Wang, Yudong Wang, Dazheng Zhang, Ting Zhou, Eric J. Tchetgen Tchetgen, Jeffrey S. Morris, Christopher R. Forrest, Yong ChenmedRxiv 2024 · DOI

Abstract

While the BNT162b2 (Pfizer-BioNTech) vaccine is known to protect against acute SARS-CoV-2 infection, its role in preventing Long COVID—clinically termed Post-Acute Sequelae of SARS-CoV-2 (PASC)—in pediatric populations remains less understood. This study evaluated the effectiveness of BNT162b2 against Long COVID across three cohorts: adolescents during the Delta phase, and both children and adolescents during the Omicron phase. Using causal mediation analysis on data from 20 health systems in the RECOVER PCORnet program, we found that the vaccine significantly reduces the risk of Long COVID. However, this protection is primarily mediated by the prevention of the initial infection rather than a reduction in PASC risk following a breakthrough infection.

Introduction

As the COVID-19 pandemic progressed, the long-term health impacts on children and adolescents became a significant public health concern. While vaccines were rapidly deployed, their effectiveness in mitigating Long COVID in younger populations was initially unclear. A major challenge in studying this is "selection bias" (specifically collider bias); comparing breakthrough infections in vaccinated individuals to infections in unvaccinated individuals can be misleading if the vaccine fundamentally alters the likelihood of infection itself.

This study sought to disentangle the vaccine's impact into two components: the indirect effect (protection gained by preventing infection entirely) and the direct effect (protection gained by altering the disease progression after an infection occurs).

Methods

Researchers conducted a real-world vaccine effectiveness study using electronic health record (EHR) data from the RECOVER PCORnet program, involving over 380,000 participants across three distinct cohorts:

  1. Adolescents (12–20 years) during the Delta phase (n=112,590)
  2. Children (5–11 years) during the Omicron phase (n=188,894)
  3. Adolescents (12–20 years) during the Omicron phase (n=84,735)

Causal Mediation Analysis

To separate the mechanisms of protection, the team employed causal mediation analysis. This framework allowed the decomposition of the "Total Effect" of the vaccine into the indirect effect (via infection prevention) and the direct effect (mitigation of PASC post-infection). To ensure the groups were comparable, propensity score weighting was used to balance variables such as age, sex, race, pre-existing conditions, and healthcare utilization patterns.

Key Results

Overall Vaccine Effectiveness (VE)

The study found substantial protection against Long COVID, though effectiveness varied by variant and age group:

  • Adolescents (Delta): 95.4% effectiveness (95% CI: 90.9% to 97.7%)
  • Adolescents (Omicron): 75.1% effectiveness (95% CI: 50.4% to 87.5%)
  • Children (Omicron): 60.2% effectiveness (95% CI: 40.3% to 73.5%)

The "Infection Prevention" Engine

The mediation analysis revealed a critical insight: the vaccine’s protection against Long COVID is almost entirely indirect.

  • Indirect Effects: Highly significant across all cohorts (Relative Risk ~0.04 for Delta adolescents; ~0.21–0.31 for Omicron cohorts). This indicates that the vaccine's primary value in preventing Long COVID lies in its ability to stop the initial infection.
  • Direct Effects: Statistically non-significant in all three cohorts (estimates ranging from 0.91 to 1.24). This suggests that if a vaccinated child experiences a breakthrough infection, their risk of developing Long COVID is statistically similar to that of an unvaccinated child who becomes infected.

Discussion and Implications

The findings underscore that BNT162b2 is a powerful tool for reducing the burden of Long COVID in the pediatric population. However, the mechanism of this protection is specific: it acts as a shield against infection rather than a modifier of post-infection sequelae.

Limitations

As an observational study using EHR data, there are inherent limitations. The rise of home testing during the Omicron wave likely led to undocumented infections, which could affect the mediation estimates. Furthermore, while propensity score weighting was rigorous, unmeasured confounders such as individual masking behaviors or social distancing practices could influence the results. The study also focused on the primary vaccine series and does not account for the potential impact of booster doses or long-term waning immunity.

Conclusion

Vaccination with BNT162b2 remains a critical strategy for preventing Long COVID in children and adolescents. Because the protection is primarily driven by preventing the initial infection, maintaining high vaccination coverage is essential to mitigating the long-term tail of the pandemic in younger populations. Future research should continue to monitor these trends as new variants emerge and clinical definitions of Long COVID are refined.

Summary updated

Abstract

Abstract Background The impact of pre-infection vaccination on the risk of long COVID remains unclear in the pediatric population. Further, it is unknown if such pre-infection vaccination can mitigate the risk of long COVID beyond its established protective benefits against SARS-CoV-2 infection. Objective To assess the effectiveness of BNT162b2 on long COVID risks with various strains of the SARS-CoV-2 virus in children and adolescents, using comparative effectiveness methods. To disentangle the overall effectiveness of the vaccine on long COVID outcomes into its independent impact and indirect impact via prevention of SARS-CoV-2 infections, using causal mediation analysis. Design Real-world vaccine effectiveness study and mediation analysis in three independent cohorts: adolescents (12 to 20 years) during the Delta phase, children (5 to 11 years) and adolescents (12 to 20 years) during the Omicron phase. Setting Twenty health systems in the RECOVER PCORnet electronic health record (EHR) Program. Participants 112,590 adolescents (88,811 vaccinated) in the Delta period, 188,894 children (101,277 vaccinated), and 84,735 adolescents (37,724 vaccinated) in the Omicron period. Exposures First dose of the BNT162b2 vaccine vs. no receipt of COVID-19 vaccine. Measurements Outcomes of interest include conclusive or probable diagnosis of long COVID following a documented SARS-CoV-2 infection, and body-system-specific condition clusters of post-acute sequelae of SARS-CoV-2 infection (PASC), such as cardiac, gastrointestinal, musculoskeletal, respiratory, and syndromic categories. The effectiveness was reported as (1-relative risk)*100 and mediating effects were reported as relative risks. Results During the Delta period, the estimated effectiveness of the BNT162b2 vaccine against long COVID among adolescents was 95.4% (95% CI: 90.9% to 97.7%). During the Omicron phase, the estimated effectiveness against long COVID among children was 60.2% (95% CI: 40.3% to 73.5%) and 75.1% (95% CI: 50.4% to 87.5%) among adolescents. The direct effect of vaccination, defined as the effect beyond their impact on SARS-CoV-2 infections, was found to be statistically non-significant in all three study cohorts, with estimates of 1.08 (95% CI: 0.75 to 1.55) in the Delta study among adolescents, 1.24 (95% CI: 0.92 to 1.66) among children and 0.91 (95% CI: 0.69 to 1.19) among adolescents in the Omicron studies. Meanwhile, the estimated indirect effects, which are effects through protecting SARS-CoV-2 infections, were estimated as 0.04 (95% CI: 0.03 to 0.05) among adolescents during Delta phase, 0.31 (95% CI: 0.23 to 0.42) among children and 0.21 (95% CI: 0.16 to 0.27) among adolescents during the Omicron period. Limitations Observational study design and potentially undocumented infection. Conclusions Our study suggests that BNT162b2 was effective in reducing risk of long COVID outcomes in children and adolescents during the Delta and Omicron periods. The mediation analysis indicates the vaccine’s effectiveness is primarily derived from its role in reducing the risk of SARS-CoV-2 infection. Primary Funding Source National Institutes of Health.
BibTeX
@misc{wu2024real,
  author = {Qiong Wu and Bingyu Zhang and Jiayi Tong and L. Charles Bailey and H. Timothy Bunnell and Jiajie Chen and Elizabeth A. Chrischilles and Dimitri Christakis and Stephen M. Downs and Kathryn Hirabayashi and Ravi Jhaveri and Aaron Mishkin and Abu Saleh Mohammad Mosa and Nathan M. Pajor and Suchitra Rao and Hanieh Razzaghi and Hayden T. Schwenk and Marion R. Sills and Huiyuan Wang and Linbo Wang and Yudong Wang and Dazheng Zhang and Ting Zhou and Eric J. Tchetgen Tchetgen and Jeffrey S. Morris and Christopher R. Forrest and Yong Chen},
  title = {{Real-world Effectiveness and Causal Mediation Study of BNT162b2 on Long COVID Risks in Children and Adolescents}},
  year = {2024},
  doi = {10.1101/2024.02.19.24302823},
  howpublished = {medRxiv},
}
Figure